PreciVax Therapeutics is developing innovative vaccines for drug-resistant bacterial infections. The company first launched its product which is a vaccine for Methicillin-resistant Staphylococcus aureus (MRSA).
| Company Name | PreciVax Therapeutics |
|---|---|
| Brand Name | PreciVax Therapeutics |
| Industries | Healthcare |
| Year of Establishment | 2017 |
| Founder(s) | Qiubin LIn |
| No. of Employees | 1-10 |
| Regional Coverage | Hong Kong |
| Clients | / |
| Stage | / |
| Investor(s) | / |
| Fundraising History | / |
| Raising Fund | / |
| Fundraising target | / |
| Pre-money valuation | / |
| Post-money Valuation | / |
| Media Exposure | |
| Company Email |
[dcb id=5586]